The present disclosure relates to compounds of Formula (I):
The present disclosure relates to compounds of Formula (I):
The present disclosure relates to compounds of Formula (I):
or pharmaceutically acceptable salts or isotopically labeled derivatives thereof, wherein A is a 6- to 10-membered bridged bicyclic heterocycloalkyl comprising at least one oxygen (O) ring atom, and R1, R2, R3, X and n as defined herein, useful in the treatment of diseases and disorders inhibited by said protein.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
The present disclosure relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, X, G1, G2, G3, W, Ring D, RD, and d are as described herein, methods of preparation, methods of treatment and prevention, and pharmaceutical compositions comprising same. The present disclosure further relates to the use of the compounds of Formula (I), and pharmaceutically acceptable salts thereof, in the treatment or prevention of TYK2-mediated conditions, diseases, and disorders.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
4.
BICYCLIC TYROSINE KINASE 2 INHIBITORS AND USES THEREOF
The present disclosure relates to compounds of Formula (I), and pharmaceutically acceptable salts and isotopically labeled derivatives thereof, wherein R1, X, G1, G2, G3, G4, G5, G6, and G7 are as described herein, methods of preparation, methods of treatment and prevention, and pharmaceutical compositions comprising same. The present disclosure further relates to the use of the compounds of Formula (I), and pharmaceutically acceptable salts and isotopically labeled derivatives thereof, in the treatment or prevention of TYK2-mediated diseases and disorders.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
6.
HEXAHYDROPYRIDO[4,3-B]INDOLYL KETONE DERIVATIVES USEFUL AS CGAS MODULATORS
The present disclosure relates to compound of Formula (I), such as compounds of Formula (II), (III), and (IV), useful for cGAS modulation, wherein L1, R1, R2, R9, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, Y, and r are described therein.
The present disclosure relates to compound of Formula (I), such as compounds of Formula (II), (III), and (IV), useful for cGAS modulation, wherein L1, R1, R2, R9, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, Y, and r are described therein.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
7.
SOLID FREEBASE FORMS OF 5-CHLORO-2-(4-((2-HYDROXY-2- METHYLPROPYL)AMINO)PYRIDO[3,4-D[PYRIDAZIN-1-YL)PHENOL FOR INHIBITING NLRP3 AND USES THEREOF
The present disclosure relates to solid state forms of Compound 1 freebase. The present disclosure also relates to processes for the preparation of the solid state forms, the pharmaceutical compositions comprising the forms, and the use thereof, e.g., in the treatment and prevention of disorders in which NLRP3 activity is implicated.
The present disclosure relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R3, R4, R4a, R4b, Z, R5, R6, R6', and R6", are described herein, and R7and R2 are joined to form a 5- to 10-membered monocyclic or bicyclic heterocyclyl or 5- to 10-membered monocyclic or bicyclic heteroaryl, and methods of preparation, methods of treatment and prevention, and pharmaceutical compositions comprising same. The present disclosure further relates to the use of the compounds of Formula (I), and pharmaceutically acceptable salts thereof, in the treatment or prevention of NLRP3-related diseases and disorders.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61P 9/00 - Drugs for disorders of the cardiovascular system
The present disclosure relates to inhibitors of NLRP3 of Formula (I):
The present disclosure relates to inhibitors of NLRP3 of Formula (I):
The present disclosure relates to inhibitors of NLRP3 of Formula (I):
or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, tautomer, isotopically labeled compound, or prodrug thereof, wherein Ring A is a 5- to 8-membered monocyclic heterocycloalkyl comprising at least one O ring atom, p is 0 or 1, and R1, R2, R3, R4, and X are as defined herein, useful in the treatment of diseases and disorders inhibited by said protein.
The present disclosure relates to inhibitors of NLRP3 of Formula (I):
The present disclosure relates to inhibitors of NLRP3 of Formula (I):
The present disclosure relates to inhibitors of NLRP3 of Formula (I):
or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, tautomer, isotopically labeled compound, or prodrug thereof, wherein Ring A is a 5- to 8-membered monocyclic heterocycloalkyl comprising at least one O ring atom, p is 0 or 1, and R1, R2, R3, R4, and X are as defined herein, useful in the treatment of diseases and disorders inhibited by said protein.
The present disclosure relates to compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein Ring A, R1, R2, Ring B, R3A, R4, p, and m are described herein, methods of preparation, methods of treatment, and pharmaceutical compositions comprising same. The present disclosure further relates to the use of the compounds of Formula (I), and pharmaceutically acceptable salts thereof, in the treatment of cGAS-related diseases and disorders.
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
14.
INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF
The present disclosure relates to compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein Ring A, R1, Ring C, R 3A, R4, m, and n are described herein, methods of preparation, methods of treatment, and pharmaceutical compositions comprising same. The present disclosure further relates to the use of the compounds of Formula (I), and pharmaceutically acceptable salts thereof, in the treatment of cGAS-related diseases and disorders.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
A61K 31/547 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame spiro-condensed or forming part of bridged ring systems
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
15.
OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF
The present disclosure relates to compounds of Formula (I):
The present disclosure relates to compounds of Formula (I):
The present disclosure relates to compounds of Formula (I):
or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, tautomer, isotopic derivative, prodrug or polymorph thereof. Further provided are pharmaceutical compositions comprising the same, methods of preparation, and methods of use and treatment, e.g., as inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
17.
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
20.
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
The present disclosure relates to inhibitors of NLRP3 of Formula (I):
4, and X are as defined herein, useful in the treatment of diseases and disorders inhibited by said protein.
The present disclosure relates to compounds of Formula (I-B) and pharmaceutically acceptable salts and tautomers thereof, wherein Ring A, Ring B, R1, R2a, R2b, R3, R4, m, n, and p are described herein, and methods of preparation, methods of treatment and prevention, and pharmaceutical compositions comprising same. The present disclosure further relates to the use of the compounds of Formula (I-B), and pharmaceutically acceptable salts and tautomers thereof, in the treatment or prevention of NLRP3-related diseases and disorders.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
22.
AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF
The present disclosure relates to compounds of Formula (I-A): and pharmaceutically acceptable salts and tautomers thereof, wherein Ring A, Ring B, R1, R2a, R2b, R3, m, n, and p are described herein, and methods of preparation, methods of treatment and prevention, and pharmaceutical compositions comprising same. The present disclosure further relates to the use of the compounds of Formula (I-A), and pharmaceutically acceptable salts and tautomers thereof, in the treatment and prevention of NLRP3-related diseases and disorders.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
23.
INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF
The present disclosure relates to compounds of Formula (I):
The present disclosure relates to compounds of Formula (I):
The present disclosure relates to compounds of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein Ring A, R1, R2, R3, R4, and m are described herein, methods of preparation, methods of treatment, and pharmaceutical compositions comprising same. The present disclosure further relates to the use of the compounds of Formula (I), and pharmaceutically acceptable salts thereof, in the treatment of cGAS-related diseases and disorders.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The present disclosure relates to compounds of Formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein Ring A, R1, R2, R3, R4, and m are described herein, methods of preparation, methods of treatment, and pharmaceutical compositions comprising same. The present disclosure further relates to the use of the compounds of Formula (I), and pharmaceutically acceptable salts thereof, in the treatment of cGAS-related diseases and disorders.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
27.
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
The present disclosure relates to inhibitors of NLRP3 of Formula (I):
4, and X are as defined herein, useful in the treatment of diseases and disorders inhibited by said protein.
The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
The present disclosure relates to compounds of Formula (I): or pharmaceutically acceptable salts or isotopically labeled derivatives thereof, wherein A is a 6- to 10- membered bridged bicyclic heterocycloalkyl comprising at least one oxygen (O) ring atom, and R1, R2, R3, X and n as defined herein, useful in the treatment of diseases and disorders inhibited by said protein.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 25/00 - Drugs for disorders of the nervous system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
There is provided a compound of formula (I): or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof. The compound of formula (I) can be useful for the treatment of a disease or condition for which a cGAS inhibitor is indicated. In some embodiments, the compound or its pharmaceutically acceptable salt, solvate, ester or prodrug thereof can be used for the treatment of an autoinflammation or an autoimmune disease such as systemic lupus erythematosus (SLE), Aicardi-Goutieres syndrome (AGS), nonalcoholic steatohepatitis (NASH), Age-dependent macular degeneration, Myocardial infarction, Acute pancreatitis, Ischemic stroke, Sporadic aortic aneurysm and dissection, Chronic lung disease, Inflammatory bowel disease, Parkinson's disease, Traumatic brain injury or Amyotrophic lateral sclerosis (ALS).
The present disclosure relates to compounds of Formula (I), or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, tautomer, isotopic derivative, prodrug or polymorph thereof. Further provided are pharmaceutical compositions comprising the same, methods of preparation, and methods of use and treatment, e.g., as inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 25/00 - Drugs for disorders of the nervous system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
The present disclosure relates to inhibitors of NLRP3 of Formula (I): (I), or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, tautomer, isotopically labeled compound, or prodrug thereof, wherein Ring A is a 5- to 8-membered monocyclic heterocycloalkyl comprising at least one O ring atom, p is 0 or 1, and R1, R2, R3, R4, and X are as defined herein, useful in the treatment of diseases and disorders inhibited by said protein.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
34.
HEXAHYDROPYRIDO[4,3-B]INDOLYL KETONE DERIVATIVES USEFUL AS CGAS MODULATORS
The present disclosure relates to compound of Formula (I), such as compounds of Formula (II), (III), and (IV), useful for cGAS modulation, wherein L1, R1, R2, R9, X1, X2, X3, X4, X5, X6, X8, X9, X10, X11, Y, and r are described therein.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
The present disclosure relates to compounds of Formula (I): (I), wherein Ring A, R1, R2, R3, and m are described herein. The present disclosure relates to the use of the compounds of Formula (I), and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, labeled isotopes, or tautomers thereof, in the treatment of cGAS-related diseases and disorders.
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/536 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
37.
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research and development services and medical research featuring identification of a solvation structure of a binding pocket of a protein and use of the solvation structure as a blueprint for small molecule drug design; research and development of new products in the fields of proteins and small molecules; scientific and medical research in the field of proteins and small molecules; scientific and engineering research services relating to protein engineering and biotechnology; computer-aided design of genetically engineered proteins and small molecules; computer-aided design of engineered proteins and small molecules
The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
C07D 237/26 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
C07D 237/34 - Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
There is provided a compound of formula (I): or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof. The compound of formula (I) can be useful for the treatment of a disease or condition for which a cGAS inhibitor is indicated. In some embodiments, the compound or its pharmaceutically acceptable salt, solvate, ester or prodrug thereof can be used for the treatment of an autoinflammation or an autoimmune disease such as systemic lupus erythematosus (SLE), Aicardi-Goutieres syndrome (AGS), nonalcoholic steatohepatitis (NASH), Age-dependent macular degeneration, Myocardial infarction, Acute pancreatitis, Ischemic stroke, Sporadic aortic aneurysm and dissection, Chronic lung disease, Inflammatory bowel disease, Parkinson's disease, Traumatic brain injury or Amyotrophic lateral sclerosis (ALS).
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
42 - Scientific, technological and industrial services, research and design
Goods & Services
Research and development services featuring a software
platform which performs mathematical and computational
chemistry for the purpose of evaluating and predicting
protein and small molecule interactions.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Small molecule pharmaceuticals for the treatment of
autoimmune and inflammatory diseases, neurological
disorders, and cancer, none of the aforesaid for the
treatment of prostate cancer. Research and development of pharmaceuticals for the
treatment of autoimmune and inflammatory diseases,
neurological disorders, and cancer.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Small molecule pharmaceuticals for the treatment of autoimmune and inflammatory diseases, neurological disorders, and cancer (1) Research and development of pharmaceuticals for the treatment of autoimmune and inflammatory diseases, neurological disorders, and cancer
42 - Scientific, technological and industrial services, research and design
Goods & Services
Research and development of pharmaceuticals for the treatment of autoimmune and inflammatory diseases, neurological disorders, and cancer; none of the foregoing relating to or for the diagnosis or treatment of musculoskeletal or soft tissue disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Small molecule pharmaceuticals for the treatment of autoimmune and inflammatory diseases, neurological disorders, and cancer, none of the aforesaid for the treatment of prostate cancer
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research and development services, namely, performing scientific research and development for others through a software platform which performs mathematical and computational chemistry for the purpose of evaluating and predicting protein and small molecule interactions
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical research, namely, research for the discovery of new drugs; scientific research, in particular in the medical, biomedical, chemical, genetic, pharmaceutical or veterinary fields; basic and applied scientific research; technical research in the field of pharmaceutical studies; Scientific and technological services, namely, screening and selecting of pharmaceutical molecules and biomarkers in the field of biopharmaceuticals for medical research purpose; Development and establishment of biological test, cell test and genetic test specifications and procedures in the field of biopharmaceuticals; Scientific and technological services, namely, functional analysis of genomics to identify, characterize, validate or develop biologically active nuclear receptors in the field of biopharmaceuticals; Scientific and technological services, namely, analysis of biological substances in biologic fluids in the field of biopharmaceuticals; Scientific and technological services, namely, conducting clinical trials namely, functional analysis to identify, characterize, validate or develop biologically active pharmaceutical molecules and biomarkers in the field of biopharmaceuticals; Scientific and technological services, namely, conducting clinical trials namely, analysis of biological substances in biologic fluids in the field of biopharmaceuticals; Computer programming in the field of scientific research and for the pharmaceutical industry; Scientific and technological services, namely, analysis in the field of biopharmaceuticals; Technology specification, namely, analyzing technology requirements and developing recommendations for the computer software and systems and other technology needed to meet those requirements, in the field of biopharmaceuticals; Professional consultancy, not connected with the conduct of business, in the fields of scientific research; research and development of new pharmaceutical products for third parties; scientific research in the field of pharmacy
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical research, namely, research for the discovery of new drugs; scientific research, in particular in the medical, biomedical, chemical, genetic, pharmaceutical or veterinary fields; basic and applied scientific research; technical research in the field of pharmaceutical studies; Scientific and technological services, namely, screening and selecting of pharmaceutical molecules and biomarkers in the field of biopharmaceuticals for medical research purpose; Development and establishment of biological test, cell test and genetic test specifications and procedures in the field of biopharmaceuticals; Scientific and technological services, namely, functional analysis of genomics to identify, characterize, validate or develop biologically active nuclear receptors in the field of biopharmaceuticals; Scientific and technological services, namely, analysis of biological substances in biologic fluids in the field of biopharmaceuticals; Scientific and technological services, namely, conducting clinical trials namely, functional analysis to identify, characterize, validate or develop biologically active pharmaceutical molecules and biomarkers in the field of biopharmaceuticals; Scientific and technological services, namely, conducting clinical trials namely, analysis of biological substances in biologic fluids in the field of biopharmaceuticals; Computer programming in the field of scientific research and for the pharmaceutical industry; Scientific and technological services, namely, analysis in the field of biopharmaceuticals; Technology specification, namely, analyzing technology requirements and developing recommendations for the computer software and systems and other technology needed to meet those requirements, in the field of biopharmaceuticals; Professional consultancy, not connected with the conduct of business, in the fields of scientific research; research and development of new pharmaceutical products for third parties; scientific research in the field of pharmacy
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical research, namely, research for the discovery of new drugs; scientific research, in particular in the medical, biomedical, chemical, genetic, pharmaceutical or veterinary fields; basic and applied scientific research; technical research in the field of pharmaceutical studies; Scientific and technological services, namely, screening and selecting of pharmaceutical molecules and biomarkers in the field of biopharmaceuticals for medical research purpose; Development and establishment of biological test, cell test and genetic test specifications and procedures in the field of biopharmaceuticals; Scientific and technological services, namely, functional analysis of genomics to identify, characterize, validate or develop biologically active nuclear receptors in the field of biopharmaceuticals; Scientific and technological services, namely, analysis of biological substances in biologic fluids in the field of biopharmaceuticals; Scientific and technological services, namely, conducting clinical trials namely, functional analysis to identify, characterize, validate or develop biologically active pharmaceutical molecules and biomarkers in the field of biopharmaceuticals; Scientific and technological services, namely, conducting clinical trials namely, analysis of biological substances in biologic fluids in the field of biopharmaceuticals; Computer programming in the field of scientific research and for the pharmaceutical industry; Scientific and technological services, namely, analysis in the field of biopharmaceuticals; Technology specification, namely, analyzing technology requirements and developing recommendations for the computer software and systems and other technology needed to meet those requirements, in the field of biopharmaceuticals; Professional consultancy, not connected with the conduct of business, in the fields of scientific research; research and development of new pharmaceutical products for third parties; scientific research in the field of pharmacy
51.
PYRIDO[4,3-B]INDOLE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS
There is provided a compound of formula (I): or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof. The compound of formula (I) can be useful for the treatment of a disease or condition for which a cGAS inhibitor is indicated. In some embodiments, the compound or its pharmaceutically acceptable salt, solvate, ester or prodrug thereof can be used for the treatment of an autoinflammation or an autoimmune disease such as systemic lupus erythematosus (SLE), Aicardi-Goutieres syndrome (AGS), nonalcoholic steatohepatitis (NASH), Age-dependent macular degeneration, Myocardial infarction, Acute pancreatitis, Ischemic stroke, Sporadic aortic aneurysm and dissection, Chronic lung disease, Inflammatory bowel disease, Parkinson's disease, Traumatic brain injury or Amyotrophic lateral sclerosis (ALS).
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
The present disclosure relates to compounds of Formula (I): (I), wherein Ring A, R1, R2, R3, and m are described herein. The present disclosure relates to the use of the compounds of Formula (I), and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, labeled isotopes, or tautomers thereof, in the treatment of cGAS-related diseases and disorders.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/536 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 37/00 - Drugs for immunological or allergic disorders
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The present disclosure relates to inhibitors of NLRP3 of Formula (I): (I), or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, tautomer, isotopically labeled compound, or prodrug thereof, wherein Ring A is a 5- to 8-membered monocyclic heterocycloalkyl comprising at least one O ring atom, p is 0 or 1, and R1, R2, R3, R4, and X are as defined herein, useful in the treatment of diseases and disorders inhibited by said protein.
The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
C07D 237/26 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
C07D 237/34 - Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
